Importantly, TrialSite also reports the American market is at | Peter A. McCullough, MD, MPH™

Importantly, TrialSite also reports the American market is at this point resoundingly rejecting the COVID-19 mRNA bivalent Omicron BA.4/BA.5 boosters as according to CDC data just four days ago only 3.6% of eligible participants have opted to receive the booster dose. If there is a fall surge in SARS-CoV-2 cases, this could represent a real quandary. https://www.trialsitenews.com/a/cdc-backed-study-reveals-disturbing-waning-in-covid-19-vaccine-effectiveness-during-omicron-f2b8ab61